Fig. 7: Endothelial PD-L1 expression affects the efficacy of anlotinib. | Cell Death & Disease

Fig. 7: Endothelial PD-L1 expression affects the efficacy of anlotinib.

From: anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells

Fig. 7

a C57BL/6 mice were injected with 1 × 106 B16 cells and tumors grew. On day 12, mice were divided into four groups (n = 8 per group), and treated with bEnd.3-vector, bEnd.3-CD274, PBS or anlotinib as shown. b Representative images of B16 tumor tissues treated as above indicated. c Left: tumor growth curve of the various treatment groups; right: Statistics of the weight of B16 tumors treated as indicated. d Representative flow images of CD4+ CD25+ FoxP3+ T cells taken from B16 tumors treated as indicated. e Statistics of the percentage of CD8+ T cells, CD8+ IFN-γ+ T cells, FoxP3+ T cells and ratio of CD8/FoxP3 in the tumors. Data are mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Back to article page